

Long-term therapy with sulphasalazine protects against colorectal cancer risk in patients with inflammatory bowel disease in Leicestershire

European Journal of Gastroenterology and Hepatology  
8, 1179-1183

DOI: 10.1097/00042737-199612000-00009

Citation Report

#	ARTICLE	IF	CITATIONS
1	Surveillance endoscopique des maladies inflammatoires chroniques de lâ€™intestin: fondement, mÃ©thodes et considÃ©rations pratiques. Acta Endoscopica, 1997, 27, 129-143.	0.0	2
4	Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut, 1998, 42, 711-714.	6.1	278
5	Risk Factors and Distinguishing Features of Cancer in IBD. Inflammatory Bowel Diseases, 1998, 4, 235-243.	0.9	15
6	Diagnostic Criteria for Inflammatory Bowel Disease in Adults. , 1999, 2, 93-105.		2
7	INFLAMMATORY BOWEL DISEASE. Primary Care - Clinics in Office Practice, 1999, 26, 141-170.	0.7	15
8	Patient Compliance and Outcomes. Inflammatory Bowel Diseases, 1999, 5, 134-137.	0.9	19
9	Colorectal cancer prevention in ulcerative colitis: a case-control study. Alimentary Pharmacology and Therapeutics, 2000, 14, 145-153.	1.9	492
10	Cyclooxygenase-2 and carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2000, 1470, M69-M78.	3.3	225
11	Pediatric inflammatory bowel disease. Current Treatment Options in Gastroenterology, 2000, 3, 403-424.	0.3	5
13	Colorectal Cancer Complicating Ulcerative Colitis: A Review. American Journal of Gastroenterology, 2000, 95, 2710-2719.	0.2	94
14	Risk of cancer in inflammatory bowel disease (IBD). European Journal of Internal Medicine, 2000, 11, 75-78.	1.0	16
15	Survival and Incidence of Colorectal Cancer in Patients with Ulcerative Colitis in Funen County Diagnosed between 1973 and 1993. Scandinavian Journal of Gastroenterology, 2000, 35, 312-317.	0.6	30
16	Inflammation, carcinogenesis and cancer. International Immunopharmacology, 2001, 1, 1651-1667.	1.7	133
17	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 2001, 48, 526-535.	6.1	2,433
18	Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. European Journal of Gastroenterology and Hepatology, 2001, 13, 1297-1301.	0.8	48
19	Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis. Annals of Internal Medicine, 2001, 134, 89.	2.0	402
20	Chemoprevention in Ulcerative Colitis: Narrowing the Gap between Clinical Practice and Research. Annals of Internal Medicine, 2001, 134, 158.	2.0	8
21	Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine. Diseases of the Colon and Rectum, 2001, 44, 77-83.	0.7	111

#	ARTICLE	IF	CITATIONS
22	Colorectal neoplasia in ulcerative colitis-recent advances. <i>Histopathology</i> , 2001, 39, 221-234.	1.6	71
23	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2001, 96, 2929-2933.	0.2	384
24	Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?. <i>Gut</i> , 2001, 48, 430-434.	6.1	90
26	Wallenberg's lateral medullary syndrome. <i>Postgraduate Medical Journal</i> , 2002, 78, 618-618.	0.9	0
27	Does patient knowledge affect the colorectal cancer risk in ulcerative colitis?. <i>Postgraduate Medical Journal</i> , 2002, 78, 615-618.	0.9	9
28	Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. <i>Gut</i> , 2002, 51, v10-v12.	6.1	337
29	Strategische Konzepte bei Diagnostik und Therapie von Dysplasien bei chronisch entzündlichen Darmerkrankungen. <i>Visceral Medicine</i> , 2002, 18, 148-154.	0.5	0
30	Colorectal Polyps in the Elderly. <i>Drugs and Aging</i> , 2002, 19, 393-404.	1.3	14
31	Malignancies in Inflammatory Bowel Disease: Fact or Fiction?. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 48-53.	0.6	48
32	Colonic dysplasia and cancer in inflammatory bowel disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 495-523.	0.6	31
34	Cancer in inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 163-171.	0.3	10
36	Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1889-1893.	1.9	30
37	Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 2053-2059.	1.9	10
38	Cancer Prevention in Inflammatory Bowel Disease and the Chemoprophylactic Potential of 5-Aminosalicylic Acid. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 356-361.	0.9	62
40	Chemoprevention of colorectal cancer in ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2003, 18, 392-400.	1.0	49
41	Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 10-14.	1.9	97
42	Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 15-21.	1.9	101
43	Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 191-198.	1.9	226

#	ARTICLE	IF	CITATIONS
44	Radical causes of cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 276-285.	12.8	1,515
45	Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. <i>Gastroenterology</i> , 2003, 125, 1576-1582.	0.6	219
46	Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. <i>Carcinogenesis</i> , 2003, 24, 443-451.	1.3	93
47	Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. <i>American Journal of Gastroenterology</i> , 2003, 98, 1682-1687.	0.2	44
48	Prevalence and management of inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1275-1280.	0.8	93
49	Does Monitoring Prevent Cancer in Inflammatory Bowel Disease?. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, S79-S83.	1.1	17
50	Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer. , 2003, 37, 1-24.		148
55	Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. <i>American Journal of Gastroenterology</i> , 2004, 99, 1371-1385.	0.2	1,021
56	Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 287-293.	1.9	205
57	Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1353-1363.	1.9	28
58	Malignitätsrisiko bei chronisch-entzündlichen Darmerkrankungen. <i>Onkologie</i> , 2004, 10, 203-212.	0.7	1
59	Chimiovention du cancer colorectal dans les maladies inflammatoires intestinales chroniques. Quels sont les médicaments proposés ?. <i>Acta Endoscopica</i> , 2004, 34, 199-213.	0.0	0
60	Histoire naturelle et facteurs de risque du cancer colorectal au cours des maladies inflammatoires intestinales. <i>Acta Endoscopica</i> , 2004, 34, 231-236.	0.0	0
61	Epidemiology of IBD during the twentieth century: an integrated view. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 463-479.	1.0	142
63	Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. <i>Gastroenterology</i> , 2004, 126, 451-459.	0.6	1,134
64	Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. <i>Gastroenterology</i> , 2004, 126, 1634-1648.	0.6	414
65	Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1088-1095.	2.4	281
66	Optimizing Therapy in Patients with Pancolitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 937-946.	0.9	8

#	ARTICLE	IF	CITATIONS
68	Practice Parameters for the Surgical Treatment of Ulcerative Colitis. Diseases of the Colon and Rectum, 2005, 48, 1997-2009.	0.7	142
70	Ulcerative colitis, colorectal cancer and colonoscopic surveillance. Scandinavian Journal of Gastroenterology, 2005, 40, 881-885.	0.6	10
71	5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 2005, 54, 1573-1578.	6.1	240
73	Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells. Cancer Research, 2005, 65, 3993-3997.	0.4	56
74	Preventing Neoplastic Progression in Ulcerative Colitis. Journal of Clinical Gastroenterology, 2005, 39, S66-S69.	1.1	20
75	Increased Risk of Intestinal Cancer in Crohn's Disease: A Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 2005, 100, 2724-2729.	0.2	500
76	Inflammatory bowel disease-related dysplasia and cancer: A referral center study in northwestern Greece. European Journal of Internal Medicine, 2005, 16, 170-175.	1.0	14
77	5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for "best evidence"? Digestive and Liver Disease, 2005, 37, 723-731.	0.4	22
78	Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies. American Journal of Gastroenterology, 2005, 100, 1345-1353.	0.2	515
79	Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice. Journal of Immunology, 2006, 176, 5015-5022.	0.4	288
80	Inflammation, a Key Event in Cancer Development. Molecular Cancer Research, 2006, 4, 221-233.	1.5	913
81	Chemoprevention for colon cancer: New opportunities, fact or fiction?. Scandinavian Journal of Gastroenterology, 2006, 41, 158-164.	0.6	14
82	Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2006, 35, 675-712.	1.0	39
83	Predictive and Protective Factors Associated With Colorectal Cancer in Ulcerative Colitis: A Case-Control Study. Gastroenterology, 2006, 130, 1941-1949.	0.6	387
84	IBD: Cancer Risk and Surveillance. , 2006, , 45-49.		0
86	Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 577-585.	1.9	261
87	Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 841-855.	1.9	106
88	Review article: maintenance therapy in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 24, 17-22.	1.9	32

#	ARTICLE	IF	CITATIONS
89	Risk factors for colorectal cancer in Crohn's colitis: A case-control study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 491-496.	0.9	46
90	Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 205-211.	0.9	188
91	Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSSEN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	228
92	Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2165-2169.	1.1	107
93	Colorectal cancer in inflammatory bowel disease: Molecular and clinical considerations. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 211-220.	0.3	21
95	Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/ $\beta$ -catenin pathway activity. <i>Carcinogenesis</i> , 2006, 27, 2371-2382.	1.3	79
96	Prevention of Colorectal Cancer in Inflammatory Bowel Disease: Value of Screening and 5-Aminosalicylates. <i>Digestion</i> , 2006, 73, 11-19.	1.2	42
97	Distal adenomatous polyps are rare in patients with inflammatory bowel disease. <i>Postgraduate Medical Journal</i> , 2006, 82, 76-78.	0.9	9
98	Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case-Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota. <i>American Journal of Gastroenterology</i> , 2007, 102, 829-836.	0.2	131
99	State of the Art Reviews: Health Benefits Related to Exercise in Patients With Chronic Low-Grade Systemic Inflammation. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 289-298.	0.8	9
100	Mechanisms of Disease: chronic inflammation and cancer in the pancreas—a potential role for pancreatic stellate cells?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 454-462.	1.7	94
101	Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study. <i>Digestion</i> , 2007, 75, 113-121.	1.2	48
102	Chemoprevention of Colorectal Cancer. <i>Digestion</i> , 2007, 76, 51-67.	1.2	72
103	Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 180-184.	0.9	54
105	Elective and Emergent Operative Management of Ulcerative Colitis. <i>Surgical Clinics of North America</i> , 2007, 87, 633-641.	0.5	26
107	Risk factors and distinguishing features of cancer in IBD. <i>Inflammatory Bowel Diseases</i> , 2007, 4, 235-243.	0.9	5
108	Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1443-1449.	1.9	27
109	The Risk of Cancer in Patients with Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 839-855.	0.7	258

#	ARTICLE	IF	CITATIONS
110	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 265-274.	0.9	70
111	Quality of life of patients with ulcerative colitis: Past, present, and future. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 554-565.	0.9	125
112	Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 763-768.	0.9	24
113	5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1341-1347.	0.9	58
114	Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1157-1166.	1.9	102
115	Strategies to Improve Adherence and Outcomes in Patients with Ulcerative Colitis. <i>Drugs</i> , 2008, 68, 2601-2609.	4.9	30
116	Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine. <i>Gastroenterology</i> , 2008, 134, 1224-1237.	0.6	103
117	Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1225-1230.	2.4	82
118	PPAR $\alpha$ is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. <i>Carcinogenesis</i> , 2008, 29, 1407-1414.	1.3	57
119	MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1049-1058.	0.9	17
120	Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 169-173.	0.8	26
121	Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. <i>Patient Preference and Adherence</i> , 2008, 2, 253.	0.8	22
122	The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 1-18.	2.2	27
123	Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. <i>World Journal of Gastroenterology</i> , 2008, 14, 3937.	1.4	367
124	A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S38.	0.1	1
125	Mesalamine Suppresses the Expression of TC22, a Novel Tropomyosin Isoform Associated with Colonic Neoplasia. <i>Molecular Pharmacology</i> , 2009, 76, 183-191.	1.0	12
126	Inflammatory bowel disease and colorectal cancer: What is new?. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 35-39.	1.0	0
127	Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. <i>Advances in Therapy</i> , 2009, 26, 936-946.	1.3	92

#	ARTICLE	IF	CITATIONS
128	Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 247-257.	1.9	157
129	Emerging drugs for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 505-521.	1.0	24
130	The long journey of salicylates in ulcerative colitis: The past and the future. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 149-156.	0.6	31
131	Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid. <i>Digestive and Liver Disease</i> , 2009, 41, 328-337.	0.4	13
132	Colon cancer: preventive agents and the present status of chemoprevention. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 211-219.	0.9	128
133	A 38-Year-Old With Recurrent Colitis. Is It Noncompliance?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1164-1167.	2.4	2
134	Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1696-1703.	1.1	57
135	Mesalazine in Inflammatory Bowel Disease: A Trendy Topic Once Again?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 127-133.	1.8	88
136	Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 281-289.	1.4	7
137	S3 Guidelines for Colorectal Carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2010, 48, 65-136.	0.2	91
138	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis – A prospective study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 171-175.	0.6	30
139	Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. <i>American Journal of Gastroenterology</i> , 2010, 105, 501-523.	0.2	1,080
140	AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2010, 138, 746-774.e4.	0.6	426
141	Inflammatory Bowel Disease Confers a Lower Risk of Colorectal Cancer to Females Than to Males. <i>Gastroenterology</i> , 2010, 138, 1697-1703.e2.	0.6	131
142	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). <i>Gut</i> , 2010, 59, 666-689.	6.1	1,000
143	Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S57-S66.	1.9	1
144	Prevalence of inflammatory bowel disease related dysplasia and cancer in 1500 colonoscopies from a referral center in northwestern Greece. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 19-23.	0.6	8
145	Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 430-442.	0.6	40



#	ARTICLE	IF	CITATIONS
146	Aminosalicylates. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 535-546.	1.0	32
147	Crohn's Disease and Colorectal Cancer. , 2011, , .		0
148	Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1115-1122.	1.9	26
149	Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 152-159.	0.9	33
150	Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 237-248.	1.4	103
151	5-Aminosalicylate Is Not Chemoprophylactic for Colorectal Cancer in IBD: A Population Based Study. <i>American Journal of Gastroenterology</i> , 2011, 106, 731-736.	0.2	103
152	The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ss-catenin signaling pathway. <i>Carcinogenesis</i> , 2012, 33, 637-643.	1.3	36
153	Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 755-764.	1.9	45
154	Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis. <i>Patient</i> , 2012, 5, 33-44.	1.1	30
155	The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis. <i>Digestive Diseases</i> , 2012, 30, 55-59.	0.8	15
156	Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010. <i>Gastroenterology</i> , 2012, 143, 382-389.	0.6	273
157	5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations. <i>American Journal of Gastroenterology</i> , 2012, 107, 1298-1304.	0.2	91
158	Colorectal Cancer in Ulcerative Colitis Patients. , 2012, , .		1
159	Ulcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives. , 0, , .		0
160	Outcome of Sporadic Adenomas and Adenoma-Like Dysplasia in Patients with Ulcerative Colitis Undergoing Polypectomy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 226-235.	0.9	67
161	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422
162	The Role of Anti-Inflammatory Drugs in Colorectal Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 131-144.	5.0	108
164	5-Aminosalicylic Acid and Chemoprevention: Does It Work?. <i>Digestive Diseases</i> , 2013, 31, 248-253.	0.8	23

#	ARTICLE	IF	CITATIONS
165	5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis. PLoS ONE, 2014, 9, e94208.	1.1	61
166	Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis. Journal of Managed Care Pharmacy, 2014, 20, 309-314.	2.2	11
167	Critical Review of the Evidence on 5-Aminosalicylate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question. Current Clinical Pharmacology, 2014, 9, 84-90.	0.2	7
168	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. American Journal of Gastroenterology, 2014, 109, 1850-1855.	0.2	21
169	Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert Review of Gastroenterology and Hepatology, 2014, 8, 329-334.	1.4	4
170	The pan-cancer analysis of gene expression patterns in the context of inflammation. Molecular BioSystems, 2014, 10, 2270.	2.9	10
171	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). Journal of Crohn's and Colitis, 2014, 8, 5-18.	0.6	110
173	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2873-2878.	0.9	18
174	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2562-2569.	0.9	31
175	Comparison of CT Colonography with Conventional Colonoscopy in Patients with Ulcerative Colitis. Academic Radiology, 2015, 22, 296-302.	1.3	8
176	Xylitol induces cell death in lung cancer A549 cells by autophagy. Biotechnology Letters, 2015, 37, 983-990.	1.1	13
177	Xcâ <sup>-</sup> inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Letters, 2015, 368, 88-96.	3.2	127
180	Colorectal Cancer and Inflammatory Bowel Disease. , 0, , .		19
181	Acetamides: chemotherapeutic agents for inflammation-associated cancers. Journal of Chemotherapy, 2016, 28, 255-265.	0.7	35
182	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2016, 14, 973-979.	2.4	56
183	Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1-12.	1.4	39
184	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1179-1192.	1.9	81
185	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324

#	ARTICLE	IF	CITATIONS
186	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. <i>Journal of Digestive Diseases</i> , 2017, 18, 566-573.	0.7	14
187	Colorectal Malignancy in a Prospective Irish Inflammatory Bowel Disease Population 15 Years Since Diagnosis: Comparison with the EC-IBD Cohort. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-7.	0.7	1
188	Adherence in ulcerative colitis: an overview. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 297-303.	0.8	41
189	Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. <i>Oncotarget</i> , 2017, 8, 1031-1045.	0.8	80
190	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 17-31.	0.6	151
191	Age Modifies the Association Between Depressive Symptoms and Adherence to Self-Testing With Telemedicine in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2648-2654.	0.9	8
192	Colorectal cancer prevention in patients with ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 103-109.	1.0	47
193	Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3763.	1.8	40
194	Surveillance for colorectal cancer and chemoprevention in ulcerative and Crohn's colitis: The need for clinical strategies to increase effectiveness. <i>JGH Open</i> , 2019, 3, 370-373.	0.7	3
195	Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-11.	0.7	46
196	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	18.1	678
197	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2905.	1.0	11
198	Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 343-351.	1.0	6
199	Colorectal Cancer: Epidemiology. , 2009, , 5-25.		7
200	Roles of inflammation in cancer initiation progression and metastasis. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 176-183.	0.8	41
201	A case of small bowel adenocarcinoma in a patient with Crohn's disease detected by PET/CT and double-balloon enteroscopy. <i>World Journal of Gastroenterology</i> , 2009, 15, 1774.	1.4	20
202	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 309.	1.4	56
203	Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete. <i>World Journal of Gastroenterology</i> , 2006, 12, 6115.	1.4	37

#	ARTICLE	IF	CITATIONS
204	Small bowel adenocarcinoma in Crohn's disease: A case report and review of literature. World Journal of Gastroenterology, 2006, 12, 1317.	1.4	24
205	5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World Journal of Gastroenterology, 2007, 13, 2872.	1.4	7
206	Duration of treatment with 5-aminosalicylic acid compounds. World Journal of Gastroenterology, 2007, 13, 4310.	1.4	12
207	Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. World Journal of Gastroenterology, 2013, 19, 4877.	1.4	16
208	Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World Journal of Hepatology, 2014, 6, 178.	0.8	47
209	Current practice and clinicians' perception of medication non-adherence in patients with inflammatory bowel disease: A survey of 98 clinicians. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8, 67.	0.6	7
210	Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease. Clinical Endoscopy, 2014, 47, 509.	0.6	37
211	Krankheiten von Verdauungstrakt, Peritoneum, Bauchwand und Pankreas. , 2001, , 776-871.		0
212	Morbus Crohn und Colitis ulcerosa. , 2003, , 900-906.		0
213	Inflammatory Diseases of the Colon, Rectum, Anus and Perianal Region. , 2003, , 335-398.		0
214	Entzündliche Erkrankungen des Dickdarms, Anorektums und Perianalbereichs. , 2003, , 347-416.		0
215	Morbus Crohn und Colitis ulcerosa. , 2007, , 933-939.		0
217	Cancer in inflammatory bowel disease: is there a chance for cancer prevention?. , 2009, , 97-106.		0
220	Colitis ulcerosa. , 1999, , 465-489.		1
222	Can we prevent cancer using current drugs?. , 0, , 205-219.		0
223	Chemopreventive effect of aminosalicylates. , 0, , 151-158.		0
224	Can we prevent inflammatory bowel disease-related colorectal cancer with 5-aminosalicylic acid, azathioprine, or 6-mercaptopurine? The clinical evidence. , 0, , 193-200.		0
225	Overcoming adherence issues in ulcerative colitis. Gastroenterology and Hepatology, 2007, 3, 795-9.	0.2	6

#	ARTICLE	IF	CITATIONS
226	Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 2212-8.	1.3	3
227	Low adherence to treatment is a weak link in the problems of ulcerative colitis. Terapevticheskii Arkhiv, 2021, 93, 1419-1427.	0.2	1
228	Secondary colon cancer in patients with ulcerative colitis: a systematic review and meta-analysis. Journal of Gastrointestinal Oncology, 2021, 12, 2882-2890.	0.6	5
229	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. Journal of Clinical Medicine, 2022, 11, 2302.	1.0	25
232	Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. Meditsinskiy Sovet, 2022, , 96-106.	0.1	0